Oral Insulin AFREZZA Successful at Controlling Blood Sugar Levels in Type 1 Diabetes Patients

June 10, 2010

Email this to someoneTweet about this on Twitter0Share on Facebook0Share on Google+0Pin on Pinterest0

MannKind  announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin (also combined with basal insulin), in reducing HbA1c levels in subjects with inadequately controlled type 1 diabetes. In addition, patients treated with AFREZZA had statistically significant lower rates of hypoglycemia, post-prandial glucose levels when measured at 30, 60, 90 and 120 minutes, and fasting blood glucose levels when compared to subcutaneously injected insulin lispro.

Add a comment

Your email address will not be published. Required fields are marked *


*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>